FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average bu	ırden								

0.5

hours per response:

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 360	11011 30(11)	or tire	invesiment	Cumpa	ally Act	01 1340							
1. Name and Address of Reporting Person* <u>Gonyer David A</u>					2. Issuer Name and Ticker or Trading Symbol Evoke Pharma Inc [EVOK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				-					,				X Directo	r		10% Ow	ner	
													X Officer below)	(give title		Other (s below)	pecify	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								President and CEO				
C/O EVOKE PHARMA, INC.					04/26/2018								Frestuent and CEO					
420 STE	VENS AVE	ENUE, SUITE 3	70															
(Street)				4	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
SOLAN	Α	٨	92075									X Form filed by One Reporting Person						
BEACH CA 92075													Form filed by More than One Reporting					
-													Person				3	
(City)	(S	tate)	(Zip)															
		Ta	ble I - Non	Derivati	vo S	curition	- A c	equired D	ieno	ead a	of or Bo	neficial	ly Owned					
					_			-	_				-	. 1		1		
Date			2. Transacti Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (In:	str.			5) Securitie Beneficia	Securities Form Beneficially (D) o		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										, 9,	t (A) or Pr							
							Code	/ A	mount	(Instr. 3 a								
			Table II - D) Oprivativ	a Sac	uritias	Δαα	uired Die	enner	ed of	or Ber	eficially	Owned					
								s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		e and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		iration	Title	Amount or Number of Shares	:	(Instr. 4)	Oil(3)			
Stock Option	\$2.43	04/26/2018		A		225,000		(1)	02/06	6/2028	Common	225,000	\$0.00	225,00	0	D		

Explanation of Responses:

1. The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the

Remarks:

/s/ Matthew J. D'Onofrio,

Attorney-in-fact for David A. 04/27/2018

<u>Gonyer</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.